Literature DB >> 8478235

Cumulative minutes with T90 greater than Tempindex is predictive of response of superficial malignancies to hyperthermia and radiation.

K A Leopold1, M W Dewhirst, T V Samulski, R K Dodge, S L George, J L Blivin, L R Prosnitz, J R Oleson.   

Abstract

PURPOSE: To better define thermal parameters related to tumor response in superficial malignancies treated with combined hyperthermia and radiation therapy. METHODS AND MATERIALS: Patients were randomized to receive one or two hyperthermia treatments per week with hyperthermia given during each week of irradiation. Hyperthermia was given for 60 min with treatments begun within 1 hr following irradiation. Power was increased to patient tolerance or normal tissue temperature of 43.0 degrees C. Irradiation was generally given 5 times per week with doses prescribed to normal tissue tolerance (generally 24-70 Gy at 1.8-2.5 Gy per fraction). Multipoint thermometry was used with temperatures obtained every 5 min.
RESULTS: One hundred eleven individual treatment fields containing 1 or more tumor nodules were completely evaluable. The complete and overall response rates were 46% and 80%, respectively. Forty-one percent of all treatment fields (51% of responding lesions) remained controlled at 2 years. Multivariate analysis revealed that the cumulative minutes that the temperature achieved by 90% of the measured tumor sites (T90) was > or = 40.0 degrees C, tumor histology, tumor volume, and radiation dose were significantly associated with complete tumor response. The complete response rate was not significantly affected by the number of hyperthermia treatments given per week. The incidence of clinically significant complications was low.
CONCLUSIONS: These results support the usefulness of the cumulative minute system in describing time-temperature relationships. The significance of thermal variables with regard to tumor response strongly supports the contention that hyperthermia can be a useful adjunct to irradiation for the local control of cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8478235     DOI: 10.1016/0360-3016(93)90314-l

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Minimum-time thermal dose control of thermal therapies.

Authors:  Dhiraj Arora; Mikhail Skliar; Robert B Roemer
Journal:  IEEE Trans Biomed Eng       Date:  2005-02       Impact factor: 4.538

2.  Direct thermal dose control of constrained focused ultrasound treatments: phantom and in vivo evaluation.

Authors:  Dhiraj Arora; Daniel Cooley; Trent Perry; Mikhail Skliar; Robert B Roemer
Journal:  Phys Med Biol       Date:  2005-04-06       Impact factor: 3.609

Review 3.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

4.  [A phase-I/II study on the local hyperthermia of cervical N2/N3 lymph node metastases].

Authors:  H Stahl; P Wust; R Graf; J Löffel; J Bier; H Riess; V Jahnke; R Felix
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

Review 5.  Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer.

Authors:  Eduardo G Moros; Jose Peñagaricano; Petr Novàk; William L Straube; Robert J Myerson
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 6.  Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial.

Authors:  B Rau; P Wust; P Hohenberger; J Löffel; M Hünerbein; C Below; J Gellermann; A Speidel; T Vogl; H Riess; R Felix; P M Schlag
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

7.  [Phase II study on preoperative radio-chemo-thermotherapy in locally advanced rectal carcinoma].

Authors:  B Rau; P Wust; J Gellermann; W Tilly; M Hünerbein; J Löffel; H Stahl; H Riess; V Budach; R Felix; P Schlag
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

8.  Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array.

Authors:  Vasant A Salgaonkar; Punit Prakash; Viola Rieke; Eugene Ozhinsky; Juan Plata; John Kurhanewicz; I-C Joe Hsu; Chris J Diederich
Journal:  Med Phys       Date:  2014-03       Impact factor: 4.071

9.  Combined treatment of inoperable carcinomas of the uterine cervix with radiotherapy and regional hyperthermia. Results of a phase II trial.

Authors:  S Dinges; C Harder; R Wurm; A Buchali; J Blohmer; J Gellermann; P Wust; H Randow; V Budach
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

Review 10.  Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters.

Authors:  S Triantopoulou; E Efstathopoulos; K Platoni; N Uzunoglou; N Kelekis; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.